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Available online 11 June 2016Background and objectives: Because there is no cure for idiopathic pulmonary artery hypertension (IPAH), im-
proving survival and stabilizing disease are key aims in any treatment strategy for patients with IPAH. Intrave-
nous (IV) administration of prostacyclin positively affects the symptoms and hemodynamic of patients with
IPAH.
This study sought to assess the efﬁcacy of cyclic Iloprost administration in Iranian patients with IPAH.
Materials and methods: This longitudinal study was conducted on 20 patients with IPAH. Upon hospitalization,
the patients received intermittent IV administration of Iloprost 6 hours a day for 5 days; this cycle was repeated
every 6 weeks, total duration of treatment was 12 months. New York Heart Association/World Health
Organization (NYHA/WHO) functional classiﬁcation (FC), 6-minute walk test (6MWT),mean pulmonary arterial
pressure (PAPm), right ventricular pressure (RVP), and serum level of N-terminal pro b-type natriuretic peptide
(NT-proBNP)were assessed at baseline, during and after completion of treatment course. The datawere analyzed
using SPSS version 13.
Results: The FC, PAPm, and RVP signiﬁcantly decreased after the treatment (P b 0.001). No change occurred in the
level of oxygen saturation during the 6MWT but the distance walked signiﬁcantly increased after the interven-
tion compared to baseline. Level of NT-proBNP signiﬁcantly decreased in patients after treatment (P = 0.009).
Conclusion: Intermittent IV administration of Iloprost decreases the FC, PAPm, RVP, and serum level of NT-proBNP
and increases the distance walked in the 6MWT by patients.
© 2016 The Society of Cardiovascular Academy. Production and hosting by Elsevier B.V. All rights reserved. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Pulmonary hypertension (PH) refers to an increase in mean
pulmonary arterial pressure (PAPm) ≥ 25 mmHg as assessed by
right heart catheterization (RHC).1 This condition can be idiopathic,
congenital, or acquired, related to diseases and conditions such as
connective tissue diseases, congenital heart disease, portal hypertension,
AIDS, and some toxins and medications such as appetite suppressing
drugs; PAH does not have a good prognosis.2–4 Idiopathic pulmonary
artery hypertension is a rare disorder with an unknown etiology, in
which occlusion of small pulmonary arteries increases the PAPm and
results in secondary right ventricular insufﬁciency.5 The prevalence of
PAH in the United States varies from4.5 to 12.3 per 100,000 population.1
In Europe, its prevalence has been reported to be 15–60 patients per one98 2126106003.
. Malekmohammad),
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diovascular Academy.
y. Production and hosting by Elsevmillion individuals.6–7 In the UK, the prevalence of PAH is 97 per one
million.1 The prevalence of PAH is 15 per onemillion, and the prevalence
of IPAH is 5.9 per one million population in France.8 Approximately 50%
of PAH patients in all registries suffer from IPAH, heritable PAH, or drug-
induced PAH.1 Thus, it can be estimated that among the 77-million
population of Iran, 150 subjects develop PAH annually.1 Considering
the survival rate of 1–2 years (without treatment), approximately 400–
450 patients in Iran suffer from IPAH. The statistics of patients registered
in the referral centers are close to this value taking into account some
related factors. Before the development of new medications, the mean
survival rate of patients with PAH was less than 3 years.2
Medications such as oxygen, calcium channel blockers, warfarin,
digoxin, and diuretics have long been used for these patients as part of
conventional therapy. Thesemedications are selected based on the cur-
rent treatment protocols for chronic cardiac and respiratory diseases
and based on the pathophysiological mechanism proposed for the left
heart congestive failure, hypoxia in patients with obstructive pulmonary
diseases, and systemic hypertension and are referred to as symptomatic
treatment.5 Calcium channel blockers (CCB) must be prescribed only for
patients with a positive response to vasodilator test; these patientsier B.V. All rights reserved. This is an open access article under the CC BY-NC-ND license
Diagram 1. Changes in the FC of patients following treatment.
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Medications recently recommended for these patients include endothelin
receptor antagonists (ERAs), soluble guanylate cyclase stimulators such as
riociguat, phosphodiesterase type 5 inhibitors (PDE-5I) such as sildenaﬁl,
and prostanoids such as epoprostenol and Iloprost.10–11
In patients with positive vasodilator test, who are categorized as
low-risk group based on clinical examinations, CCB is the ﬁrst choice
of treatment. If CCB do not improve the patient's condition, speciﬁc
treatment with oral ERAs such as bosentan or PDE-5Is such as sildenaﬁl
may be started. For low-risk patients with a negative vasodilator test,
treatment with one of the speciﬁc medications is started.1 For high-risk
patients with a negative test, continuous treatment with IV prostacyclin
can be effective; in such cases, epoprostenol, treprostinil, or Iloprost is
the ﬁrst choice of treatment.12
Prostacyclin (PGI2) is a strong vasodilator, which prevents the pro-
liferation of endothelial smooth muscle cells; however, the synthesis
of prostacyclin decreases in IPAH.11 Evidence shows that administration
of IV prostacyclin along with conventional treatments for more than
12 weeks can positively affect exercise capacity, FC, and hemodynamic
of cardiovascular patients.13 Prostacyclin is an important homeostasis
regulator and is a strong short-acting prostanoid produced in the vascular
endothelium. Iloprost-β-cyclodextrin clathrate, also known as Iloprost, is
a synthetic, chemically strong, and stable prostacyclin.14–15 Iloprost is an
analog of epoprostenol, also known as prostacyclin (PGI2), whichmimics
the pharmaceutical properties of epoprostenol. It prevents platelet aggre-
gation in vessels, causes vascular dilation, and enhances the blood ﬂow
through the vessels; thus, it also prevents polycythemia.14,16 This drug
can be administered via three routes of oral, inhalation, and injection.11
This drug is most commonly administered intravenously.16 Intrave-
nous administration of Iloprost requires hospitalization since patients
should bemonitored for the side effects of the drug during administration
such as tachycardia, hypotension,17 headache, andﬂushing.16 Iloprost and
epoprostenol are chemically similar with the exception that Iloprost is
more stable, readily available, and easier for use at home.18 Iloprost de-
creases the resistance of peripheral vessels and themean arterial pressure
while it increases the cardiac index and heart rate. Also, it increases the
renal blood ﬂow19 but has a natriuretic effect and increases the excretion
of sodium in urine; however, this is independent of the related hemody-
namic changes.16The clearance of this drug is 15–20mL/kg/min and has a
half-life of 5–20min.Most of it (70%) is excreted through the kidneys and
12–17% is excreted via other routes.15 To obtain an effective plasma level,
it must be continuously infused in an amount of 1–2 ng/kg/min.19 By
introduction of new medications such as epoprostenol and Iloprost,
1-year and 3-year survival rates of patients increased by 68–88%.20
Iloprost is administered in IPAH patients in two forms of continuous21
and intermittent or cyclic infusion.12 Continuous infusion requires
adequate vascular access obtained by insertion of a permanent catheter
in the subclavian vein and the drug is delivered to the patient by
CADD1 infusion pumps. The drug is administeredwith the initial infusion
rate of 0.5 ng/kg/min, which is gradually increased as long as no unbear-
able side effects occur. After hospital discharge, patients are visited in an
outpatient setting every 6–12 weeks. In case of satisfactory clinical out-
comes (based on the opinions of the attending physician and patients),
the drug dosage does not change. In case of no change or aggravation of
disease, the drug dosage increases unless unbearable side effects occur.
Each patient visit must include history taking, physical examination, and
6MWT along with functional assessment using FC.22 In intermittent or
cyclic infusion, Iloprost is administered for ﬁve consecutive days for
6 hours a day. This cycle is repeated every 6 weeks. The initial infusion
rate is 0.5 ng/kg/min, which later increases to 2 ng/kg/min.9,12
Following the initiation of treatment, its outcome must be evalu-
ated in patients. Several tools are available for outcome assessment
in IPAH patients such as echocardiography, assessment of hemody-
namic parameters,23 6MWT,24 biochemical markers such as serum
uric acid,25–26 FC,27 and NT-proBNP.28 Echocardiography is a non-
invasive method suitable for primary and outcome assessments oftreatment in these patients. Thismodality provides valuable information
about the hemodynamic status of the right heart such as PAPm, status of
the right and left ventricles, and atriums.29–31 The 6MWT is affordable,
simple, reproducible, standard, and objective24 and has been introduced
as the gold standard for the assessment of the treatment outcome in PAH
patients by the European Agency for Evaluation of Medicinal Products
and the Food and Drug Administration.32–33 The 6MWT is the most
important criterion for assessment of treatment outcome and severity
of disease in patients in the clinical setting and in clinical trials for
research purposes.34 The level of NT-proBNP increases in IPAH patients
by a reduction in the right ventricular function.35 Studies show that in
patientswith PAH, the level of NT-proBNP is correlated to the functional28
and hemodynamic36 status of patients and can be used as a predictor of
the survival of patients.35,37
Considering the high cost of prostacyclin medications18 particularly
in Iran, patients often cannot afford continuous treatment with this
medication. Thus, patients who require IV prostacyclin according to
the guidelines can only receive this drug in a cyclic fashion by hospitaliza-
tion for 5days permonth and repeat this cycle every 6weeks. Noprevious
study has assessed the outcome and efﬁcacy of cyclic administration of
Iloprost in IPAH patients and the available ones have only focused on
connective tissue diseases. Therefore, this study sought to assess the
outcome and efﬁcacy of cyclic treatment with Iloprost in Iranian patients
with IPAH.
Materials and methods
This longitudinal study was conducted during 2011–2013 on patients
presenting to Masih Daneshvari Hospital due to mean pulmonary artery
pressure (mPAH). Only 20 patients during the above-mentioned time
period required treatment with IV Iloprost. The inclusion criteria were
deﬁnite diagnosis of IPAH based on right ventricular catheterization and
the expert opinions of the cardiologists and pulmonologists of Masih
Daneshvari Hospital, the need for treatment with IV Iloprost, andwilling-
ness for participation in the study. Datawere collected using a researcher-
designed questionnaire. This questionnaire included demographic
information (age, sex, height, and weight of patients and duration of
disease), FC, 6MWT (distance walked and drop in O2 saturation), echo-
cardiographic ﬁndings (PAPm and RVP), hemodynamics on right
ventricular catheterization (PAPm and atrial pressure), and level of
NT-proBNP at baseline, in the ﬁrst 6 weeks, in the second 6 weeks,
and in the third 6 weeks of the study. The demographic part of the
questionnaire was ﬁlled out by interviewing patients and the sections
regarding clinical and paraclinical tests were ﬁlled out by the research
supervisor based on the opinions of cardiologists and pulmonologists of
Masih Daneshvari Hospital. The validity and reliability of these clinical
and paraclinical tests have been assessed in several studies and the
6MWT is also known as the gold standard for assessment of patients
with IPAH.32,34 These tests are routinely performed for assessment of
the course of treatment in IPAHpatients hospitalized inMasihDaneshvari
Hospital. After explaining the objectives of the study to patients, written
informed consent was obtained from them. Patients were informed that
they were free to leave at any time and that not participating in this
study would not affect their course of treatment. Also, patients were
ensured about the conﬁdentiality of their information. Each patient
Table 1
Demographic factor and base line characteristics.
n Gender Age
NYHA
class
PAP
cath
PAP
echo NT-proBNP 6MWT
1 F 27 III 75 75 760 538
2 F 37 III 80 80 854 423
3 F 30 III 85 90 208 375
4 F 38 IV 100 110 2250 183
5 F 37 III 95 95 1940 247
6 F 45 III 75 80 1264 305
7 F 28 IV 100 110 3280 195
8 F 27 III 90 95 1672 453
9 F 41 III 65 80 960 310
10 F 43 III 95 95 845 341
11 F 35 III 70 80 1250 275
12 F 37 IV 110 110 4783 175
13 F 28 III 65 85 1760 257
14 F 32 IV 110 120 7413 154
15 F 34 III 60 65 1452 196
16 F 31 IV 120 120 5340 60
17 F 34 III 95 90 986 327
18 F 24 III 65 80 705 231
19 F 40 III 85 85 604 510
20 F 32 III 75 80 965 192
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ined and treated. Prior to treatment, the questionnaire was ﬁlled out for
patients requiring IV Iloprost who gave their written informed consent
for participation in this study; IV Iloprost was then administered
according to the protocol. The intermittent or cyclic protocol includes
IV administration of Iloprost for ﬁve consecutive days for 6 hours
daily. In this study, after hospitalization, the patients received IV
Iloprost 6 hours a day for 5 days and then every 6weeks after discharge.
The initial infusion rate was 0.5 ng/kg/min at ﬁrst, which was then
increased to 2 ng/kg/min. The dose titrated up as long as no unbearable
side effects occur within 2 h of Iloprost infusion. All of these patients
also received 50 mg sildenaﬁl daily and 125 mg bosentan twice daily
during the study period. During the course of treatment, serum level
of NT-proBNP was measured at each hospitalization. Echocardiography
and FC were assessed. After the third injection, patients performed the
6MWT for assessment of functional capacity. The data were analyzed
using SPSS version 13 and repeated-measures ANOVA, Friedman test,
and the Pearson's correlation coefﬁcient.Results
All patients were females with a mean age of 34 ± 5.8 years. The
mean height of patients was 160 ± 5 cm, the mean weight was 61 ±
14 kg, and the duration of disease was 3 ± 1 years.
The results of cardiac catheterization showed that the PAPm was
85.75 ± 17 mmHg and the right atrial pressure was 14 ± 3 mmHg
before treatment. Before the IV administration of Iloprost, 75% of
patients were FC III and 25% were FC IV. While after treatment with IV
Iloprost, 70% of patients were FC II, 20% were FC III, and 10% were FC
IV. Diagram1 shows changes in the FC of patients compared to baseline.
The Friedman test showed that the FCof patients signiﬁcantly decreased
compared to baseline (P b 0.001).Table 2
Changes in PAPm and RVP.
Time points Variable Baseline First infusion
Mean Sd Mean Sd
Echocardiography PAPm 91 25 90 22
RVP 88 26 88 20
Catheterization PAPm 85.75 17 – –Diagram 1 shows echocardiographic changes in PAPm and RVP of
patients. Repeated-measures ANOVA showed that PAPm and RVP of
patients signiﬁcantly decreased in post-treatment echocardiography.
The results also showed that the maximum and minimum distance
walked was 538 and 60 m, respectively, in the 6MWT. Table 2 shows
the mean and standard deviation of the distance walked in the 6MWT
and the reduction in oxygen saturation rate during the test and at the
end of study compared to baseline. As seen, no change was noted with
regard to reduction in oxygen saturation during the test. However,
walked distance at the end of study increased compared to baseline.
(See Table 1.) (See Table 3.)
The highest and the lowest levels of NT-proBNP were 7413 pg/mL
and 208 pg/mL, respectively, at baseline with a mean value of 1964 ±
1760 pg/mL. At the end of study, level of NT-proBNP increased in 5
patients (25%) and decreased in 15 patients (75%) compared to baseline.
Diagram 2 shows the changes in NT-proBNP during the study. Repeated-
measures ANOVA showed that the level of NT-proBNP in patients
signiﬁcantly decreased post-treatment (P = 0.009).
Discussion
Based on the results, intermittent IV administration of Iloprost effec-
tively decreased FC, PAPm, RVP, and level of NT-proBNP and increased
the distance walked in the 6MWT but blood oxygen saturation were not
changed. Functional class is among the most important indicators of
prognosis in patients with PAH. It has also been used in preliminary stud-
ies for assessment of the course of treatment in patients.27 Higenbottam
et al. showed that FC is among the most important predictors of PAH
especially in class III and IV patients compared to class I and II subjects
who receive Iloprost or epoprostenol for long periods of time.18 Prior to
the initiation of treatment with Iloprost, most patients had FC III and IV.
But after intermittent treatment with Iloprost, many patients improved
to FC. The PAPm is another predictor of disease status. The results of our
study showed that the mean PAPm decreased in patients receiving inter-
mittent IV infusion of Iloprost for long periods of time. Caravita et al.
reported that long-term intermittent IV infusion of Iloprost in patients
with connective tissue diseases decreased PAPm, inhibited PAH, and
prevented the aggravation of disease.9 Caramaschi et al. evaluated the
efﬁcacy of cyclic IV infusion of Iloprost to prevent PAH in patients with
systemic sclerosis and reported that cyclic infusion of Iloprost for
15 months prevented PAH in these patients.12 Bartman et al. showed
that cyclic infusion of Iloprost prevented PAH in patients with systemic
sclerosis.38 Niewierowicz et al. in 199539 and Bartosik et al. in 1996
evaluated the efﬁcacy of cyclic infusion of Iloprost for treatment of
PAH in a number of patients with systemic sclerosis and reported the
same results.40 In all these studies, echocardiographywas used tomonitor
the patients' status and PAPm. In contrast, Higenbottam et al., in their
study, stated that the mean PAPm especially in patients receiving prosta-
glandin was not a suitable predictor of disease status or the course of
treatment.18
Although the pulmonary vascular resistance2,41 and the mean
pressure of the right atrium are among the most important predictors of
disease status and course of treatment in patients with PAH,27,41 their
measurement requires right heart catheterization. In the current study
similar to some previous investigations,9,12,38,40 right heart catheteriza-
tion was performed for patients at baseline to conﬁrm the diagnosis. ToSecond infusion Third infusion Repeated-measures ANOVA
Mean Sd Mean Sd
85 21 81 22 P b 0.001
84 20 80 22 P = 0.050
– – – –
Diagram 2. Changes in the mean level of NT-proBNP following treatment.
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were done. Echocardiography is a non-invasive method for primary
assessment of the course andoutcomeof treatment andprovides valuable
information regarding the hemodynamics of the right heart.29,31 It should
be noted that each diagnostic procedure should be done based on the
opinions of the experts and the patient's need. New guidelines on the
control and treatment of PAH clearly state that repeat of cardiac catheter-
ization is only allowed if the patient's condition has worsened or a
modiﬁcation has occurred in the type of treatment administered.1 Since
the condition of none of the patients in our study was worsened and
there was no need to change the type of drug, repeat of right heart
catheterization was not ethical.
In the 6MWT, no changewas notedwith regard to oxygen saturation
rate during the test (P = 0.244). However, the distance walked in the
6MWT signiﬁcantly increased post-treatment compared to baseline
(P b 0.001). Caravita et al. showed signiﬁcant increase in the distance
walked in the 6MWT after IV infusion of Iloprost.9
Although the level of NT-proBNP decreased in only 75% of patients
compared to baseline, statistical tests indicated a signiﬁcant reduc-
tion in level of NT-proBNP in patients (P = 0.009). Evidence shows
that in PAH, level of NT-proBNP is related to the functional status28
and hemodynamics36 of patients and it can be used as a predictor of
survival of patients.35,37 The results of studies in this regard indicate that
in patients with PAH, the level of NT-proBNP has a strong inverse
correlation with right ventricular insufﬁciency, and the plasma
level of NT-proBNP is a predictor ofmortality in these patients. The results
of previous studies have also shown that patients with NT-proBNP ≥
150 pg/mL have lower survival rates.35 In the study by Caravita et al., a
signiﬁcant correlation was noted between PAPm and serum level of
NT-proBNP; NT-proBNP and PAPm were also reported to have a signiﬁ-
cant reverse correlation with the distance walked in the 6MWT.9Conclusion
The results of this study showed that intermittent IV administration
of Iloprost in patients with PAH decreased the FC, PAPm, RVP, and level
of NT-proBNP and increased the distance walked in the 6MWT. Since
the palliative care has not been well addressed in the PAH literature,
intermittent IV administration of Iloprost can be as the palliative care
in IPAH with FC III and IV.Limitation
The effect of treatment can not only be explained by the Iloprost,
because all of these patients also received sildenaﬁl and bosentan dur-
ing the study period and ethically we could not stop basic treatment
of patients. Also patients were followed only with echocardiography
because none of our patient's condition has worsened and nomodiﬁca-
tion has occurred in the type of treatment administered.Source of funding
This studywas funded by a grant from the National Research Institute
of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University
of Medical Sciences, Tehran, Iran.Table 3
Comparison of the results of 6MWT at baseline and at the end of study.
Time
Variable
Baseline End of study Paired t-test
Mean Sd Mean Sd
Distance walked in meters 287 124 351 114 p b 0/001
Reduction in oxygen saturation 7 8 6 4 P = 0/244Financial/nonﬁnancial disclosures
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